natgillin/translations-raw huggingface dataset:
Infusion-related adverse reactions have been reported with anidulafungin in clinical studies, including flushing, hot flush, pruritus, rash, and urticaria, summarized in Table 1.
Med uporabo anidulafungina v kliničnih študijah so poročali o neželenih učinkih, povezanih z infundiranjem, ki so vključevali pordevanje/vročinske oblive, pruritus, izpuščaj in urtikarijo ter so povzeti v preglednici 1.
Infusion-related chest pain5, infusion-related reaction primarily presented as back pain5, 6.
z infundiranjem povezana bolečina v prsih5, z infundiranjem povezana reakcija, ki se izraža predvsem kot bolečina v križu5, 6
Infusion-related reaction
učinki, povezani z infundiranjem
Infusion-related reaction, asthenia/fatigue, pyrexia/body temperature increased
reakcije, povezane z infundiranjem, astenija/utrujenost, pireksija/zvišana telesna temperatura
Infusion-related reaction1
z infundiranjem povezane reakcije1
Infusion-related reaction: Infusion-related reactions may happen during treatment because Cyramza is given as an intravenous infusion via a drip (see section 3).
Reakcija, povezana z infuzijo: Med zdravljenjem se lahko pojavijo reakcije, povezane z infuzijo, saj zdravilo Cyramza dajemo intravensko (kapalna infuzija) (glejte poglavje 3).
Infusion-related reactiona
infuzijska reakcijaa
Infusion-related reactions
Neželeni učinki, povezani z infundiranjem
infusion-related reactions
z infuzijo povezana reakcija
infusion-related reactions (drug hypersensitivity, anaphylactic reaction, hypersensitivity and cytokine release syndrome)
z infuzijo povezane reakcije (preobčutljivost za zdravilo, anafilaktična reakcija, preobčutljivost in sindrom sproščanja citokinov)
Infusion-related reactions (due to cytokine release), characterized by one or more of the following symptoms -have been reported: flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia.
Opisane so bile z infundiranjem povezane reakcije (zaradi sproščanja citokinov), za katere je značilen eden ali več od naslednjih simptomov: rdečica, mrzlica, zvišana telesna temperatura, dispneja, hipotenzija, piskajoče dihanje, bronhospazem in tahikardija.
Infusion-related reactions (including cytokine-release syndrome, tumour-lysis syndrome), see section 4.4.
z infuzijo povezane reakcije (vključno s sindromom sproščanja citokinov, sindromom razpada tumorja), glejte poglavje 4.4;
Infusion-related reactions (IRRs)
Reakcije, povezane z infuzijo (IRR, infusion-related reactions)
Infusion-related reactions (IRRs) were reported in approximately half of all patients treated with DARZALEX.
O infuzijskih reakcijah so poročali pri približno polovici bolnikov, ki so prejemali zdravilo DARZALEX.
infusion-related reactions associated with KEYTRUDA use and on how to manage them and to enhance the awareness of patients and/or their caregivers on the signs and symptoms relevant to the early recognition/identification of those adverse events.
z infuzijo povezanih reakcijah, povezanih z uporabo zdravila KEYTRUDA, kako jih obvladati in povečati ozaveščenost bolnikov in/ali njihovih skrbnikov o znakih in simptomih, pomembnih pri zgodnjem odkrivanju/prepoznavanju teh neželenih učinkov.
Infusion-related reactions can occur after initiation of any infusion, in spite of patients being pre- medicated with oral antihistamine, intravenous corticosteroid and/or paracetamol, and generally during or within 1 hour after the infusion is completed.
Reakcije, povezane z infundiranjem, se lahko pojavijo po začetku katerega koli infundiranja kljub predhodnemu zdravljenju z antihistaminikom, intravenskim kortikosteroidom in/ali paracetamolom ter navadno med infundiranjem ali 1 uro po koncu infundiranja.
Infusion-related reactions have been reported with belatacept administration in clinical studies.
V kliničnih študijah so pri uporabi belatacepta poročali o pojavu infuzijskih reakcij.
Infusion-related reactions have been reported with belatacept administration in the clinical studies.
V kliničnih študijah so pri uporabi belatacepta poročali o pojavu infuzijskih reakcij.
Infusion-related reactions include but are not limited to the following multiple adverse reaction terms: nasal congestion, cough, chills, allergic rhinitis, throat irritation, dyspnoea, nausea (all ≥ 5%), bronchospasm (2.6%), hypertension (1.3%) and hypoxia (1.3%).
Izraz infuzijske reakcije vključuje tudi več drugih neželenih učinkov, med drugim naslednje: kongestija nosne sluznice, kašelj, mrazenje, alergijski rinitis, draženje žrela, dispneja, navzea (vsi ≥5%), bronhospazem (2,6%), hipertenzija (1,3%) in hipoksija (1,3%).
Infusion-related reactions or allergic reactions: Kadcyla can cause flushing, shivering fits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden swelling of your face, tongue, or trouble swallowing during the infusion or after the infusion on the first day of treatment.
Z infundiranjem povezane reakcije ali alergijske reakcije: Zdravilo Kadcyla lahko povzroči rdečico, napade mrazenja, zvišano telesno temperaturo, težave z dihanjem, nizek krvni tlak, hitro bitje srca, nenadno oteklost obraza, jezika ali težave s požiranjem med infundiranjem zdravila ali prvi dan zdravljenja po njem.
Infusion-related reactions showed a tendency to occur in a greater proportion of patients with over 100 kg bodyweight.
Reakcije, povezane z infundiranjem, so se pojavile pri večjem deležu bolnikov s telesno maso nad 100 kg.
Infusion-related reactions were reported in 4% of patients receiving vedolizumab.
O reakcijah, povezanih z infundiranjem, so poročali pri 4 % bolnikov, ki so prejemali vedolizumab.
Infusion-related reactions*, pyrexia
z infundiranjem povezane reakcije*, pireksija
Infusion-related side effects
Neželeni učinki, povezani z infundiranjem
infusion-site
mestu infundiranja
Infusion-site cellulitisa
celulitis na mestu infundiranjaa
Infusions 1 and 2: schedule
1. in 2. infundiranje: časovni razpored:
Infusions 1 and 2: schedule
in 2. infundiranje: časovni razpored
Infusions 2 to 13: schedule
Urnik od 2. do 13. infuzije:
Infusions 3 to 12: schedule
3. do 12. infundiranje: časovni razpored
Infusions must be administered under the close supervision of an experienced physician with full resuscitation facilities immediately available (for radiopharmaceutical precautions see also sections ‘4.2 and 12’).
Infuzijo se daje pod skrbnim nadzorom izkušenega zdravnika v prostoru, ki je ustrezno opremljen s celotno, takoj dosegljivo opremo za oživljanje (za previdnostne ukrepe v zvezi z radiofarmaki glejte tudi poglavji 4.2 in 12).
Infusions of blood products must not occur simultaneously with Voriconazole Hospira.
Infuzije krvnih pripravkov se ne sme dajati hkrati z zdravilom Vorikonazol Hospira .
Ingelvac CircoFLEX can cause a mild, temporary increase in body temperature, usually on the day of vaccination.
Cepivo Ingelvac CircoFLEX lahko povzroči blago, začasno zvišanje telesne temperature, ponavadi na dan cepljenja.
Ingelvac CircoFLEX contains small amounts of a protein from PCV2.
Cepivo Ingelvac CircoFLEX vsebuje majhne količine beljakovine PCV2.
Ingelvac CircoFLEX is a vaccine for use in pigs, which is available as a suspension for injection.
Zdravilo Ingelvac CircoFLEX je cepivo za prašiče, ki je na voljo kot suspenzija za injiciranje.
Ingelvac CircoFLEX is used to vaccinate pigs from two weeks of age against PCV2 infection.
Zdravilo Ingelvac CircoFLEX se uporablja za cepljenje prašičev od dveh tednov starosti naprej proti okužbi s PCV2.
Ingenol mebutate gel did not demonstrate any potential for photo irritation or photo allergic effects.
Gel z ingenol mebutatom ni pokazal nobenega potenciala za draženje zaradi svetlobe ali za fotoalergijske učinke.
Ingestion
Zaužitje
Ingestion can be harmful to children and pregnant women.
Zaužitje lahko škoduje otrokom ali nosečim ženskam.
Ingestion can be lethal.
Zaužitje je smrtno nevarno.
Ingestion can be lethal.
Zaužitje lahko povzroči smrt.
Ingestion of 100 mg oral oxybutynin chloride in association with alcohol has been reported in a 13 year old boy who experienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine.
Peroralno jemanje 100 mg oksibutinin klorida v povezavi z alkoholom pri 13-letnem fantu je pokazalo izgubo spomina, pri 34-letni ženski pa se je pojavil stupor, ki mu je sledila motnja orientacije in vznemirjenost, ko se je zbudila, razširjene zenice, srčna aritmija in zastoj urina.
Ingestion of 20 mg/kg elemental iron is potentially toxic and 200-250 mg/kg is potentially fatal.
Zaužitje 20 mg/kg elementarnega železa je potencialno toksično, odmerek 200–250 mg/kg pa je potencialno smrten.
Ingestion of ritonavir with food results in lower ritonavir exposure than ingestion in the fasted state.
Zaužitje ritonavirja s hrano povzroči manjšo izpostavljenost ritonavirju kot zaužitje na tešče.
Ingestion of the 5 ml bottle content corresponds to an oral dose of less than 5 mg bromfenac, which is 30 times lower than daily dose of bromfenac oral formulation formerly used.
Zaužitje 5 ml vsebine plastenke ustreza peroralnemu odmerku manj kot 5 mg bromfenaka, kar je 30-krat manj, kot je običajni peroralni dnevni odmerek bromfenaka.
Ingestion of vortioxetine in the dose range of 40 to 75 mg has caused an aggravation of the following adverse reactions: nausea, postural dizziness, diarrhoea, abdominal discomfort, generalised pruritus, somnolence and flushing.
Zaužitje vortioksetina v razponu odmerkov od 40 do 75 mg je povzročilo poslabšanje naslednjih neželenih učinkov: navzeje, posturalne vrtoglavice, diareje, bolečine v trebuhu, generaliziranega srbenja, zaspanosti in zardevanja.
ingle use pre-filled pen
1 napolnjen injekcijski peresnik za enkratno uporabo
Ingredients in the blue, immediate-release layer: maize starch, microcrystalline cellulose, edetate disodium, citric acid, stearic acid and colorant (Indigo Carmine E132, Aluminum lake).
Sestavine v modri plasti za takojšnje sproščanje: koruzni škrob, mikrokristalna celuloza, dinatrijev edetat, citronska kislina, stearinska kislina in barvilo (indigotin E132).
Ingredients in the white, sustained-release layer: hypromellose 2208, microcrystalline cellulose, povidone K30, silicon dioxide and magnesium stearate.
Sestavine v beli plasti za podaljšano sproščanje: hipromeloza 2208, mikrokristalna celuloza, povidon K30, silicijev dioksid in magnezijev stearat.
ingrowing hairs
dlake, ki se vraščajo
Ingrown hair, oedema face, dermatitis, oedema mouth, papular rash, bleeding skin, herpes simplex, eczema, cheilitis, furunculosis, contact dermatitis, abnormal hair texture and abnormal hair growth, hypopigmentation, flushing skin, lip numbness, skin soreness
vraščanje dlak, obrazni edem, dermatitis, edem ust, papulozni izpuščaj, krvaveča koža, herpes simplex, ekcem, heilitis, furunkuloza, kontaktni dermatitis, nenormalna sestava las, nenormalna rast las, hipopigmentacija, rdečina kože, otrplost ustnic, boleča koža
ingrown toenails with or without infection
vraščeni nohti na prstih nog z okužbo ali brez
Inhalation gas
Inhalacijski plin
Inhalation gas
plin za inhaliranje
Inhalation gas.
Inhalacijski plin.
Inhalation gas.
plin za inhaliranje
Inhalation gas.
Plin za inhaliranje.
inhalation in the morning and 1 inhalation in the evening or inhalations in the morning or
vdih zjutraj in 1 vdih zvečer ali vdiha zjutraj ali
Inhalation of nebulised tobramycin produces high sputum concentrations and low plasma levels.
Po inhalaciji tobramicina z nebulatorjem so bile koncentracije v izpljunku visoke in koncentracije v plazmi nizke.
Inhalation of the vapour and contact with the skin and mucosa, particularly that of the eyes, must be avoided.
Preprečite vdihavanje hlapov in stik s kožo in sluznico, zlasti očmi.
Inhalation of the vapour and contact with the skin and mucous membranes, especially the eyes, must be avoided.
Preprečite vdihavanje hlapov in stik s kožo in sluznico, zlasti očmi.
Inhalation powder
prašek za inhaliranje
Inhalation powder pre-dispensed
prašek za inhaliranje, odmerjen
Inhalation powder,
prašek za
Inhalation powder, hard capsule (inhalation powder)
prašek za inhaliranje, trde kapsule (prašek za inhaliranje)
Inhalation powder, pre-
Prašek za inhaliranje,
Inhalation powder, pre-dispensed (Inhalation powder).
Prašek za inhaliranje, odmerjeni.
Inhalation powder.
Prašek za inhaliranje.
Inhalation should be performed by applying a normal breathing pattern without interruption.
Zdravilo se inhalira v običajnem vzorcu dihanja brez prekinitev.
Inhalation use
inhalacijska uporaba
Inhalation use
Inhalacisjka uporaba
Inhalation use
Inhaliranje
Inhalation use
Za inhaliranje.
Inhalation use only.
Samo za inhalacijo.
Inhalation use, ONCE DAILY
za inhaliranje ENKRAT NA DAN
Inhalation vapour, liquid
EU/2/02/035/007 SevoFlo 100% Para za inhaliranje, tekočina
Inhalation vapour, liquid
Para za inhaliranje, tekočina
Inhalation vapour, liquid
Para za inhaliranje, tekočina.
Inhalation vapour, liquid for dogs, 100% sevoflurane
Para za inhaliranje, tekočina za pse, 100 % sevofluran
Inhalation vapour, liquid for dogs, 100% v/v sevoflurane
Para za inhaliranje, tekočina za pse, 100 % v/v sevofluran.
Inhale
Inhalirajte
Inhale by mouth the full content of one ampoule in the morning, and one ampoule in the evening using the Tolero nebuliser handset.
Celotno vsebino ampule zjutraj inhalirajte skozi usta, eno ampulo pa zvečer z uporabo nebulatorja Tolero.
Inhale the capsule – 1st breath:
Inhalirajte vsebino kapsule – prvi vdih:
Inhale the capsule – 2nd breath:
Inhalirajte vsebino kapsule – drugi vdih:
Inhale the contents of the capsule using the inhaler, with one or two breaths in.
Vsebino kapsul vdihnite z inhalatorjem z enim ali dvema vdihoma.
Inhale the medicine
Vdihnite zdravilo:
Inhale the medicine again by repeating steps 8 and 9.
Ponovno poskusite inhalirati zdravilo, tako da ponovite 8. in 9. korak.
Inhale the medicine again by repeating steps 9 and 10.
Ponovno poskusite inhalirati zdravilo, tako da ponovite 9. in 10. korak.
Inhale the medicine:
Vdihnite zdravilo:
Inhale the powder deeply with a single continuous inhalation.
Z enim samim neprekinjenim vdihom globoko vdihnite prašek.
Inhale with one long, steady, deep breath in.
Vdihnite z enim dolgim, enakomernim, globokim vdihom.
Inhale your insulin dose
Vdihnite odmerek insulina
Inhale your medicine
Vdihnite zdravilo
Inhale your medicine as follows:
Zdravilo inhalirajte, kot sledi:
INHALED BETA AGONIST
INHALACIJSKI AGONISTI ADRENERGIČNIH RECEPTORJEV BETA
INHALED BETA AGONIST
INHALIRANI AGONISTI BETA
INHALED BETA AGONISTS
AGONISTI ADRENERGIČNIH RECEPTORJEV BETA
INHALED BETA AGONISTS
INHALACIJSKI AGONISTI ADRENERGIČNIH RECEPTORJEV BETA
INHALED BETA AGONISTS
INHALIRANI AGONISTI BETA
Inhaled bronchodilators
inhaliranje bronhodilatatorjev,
Inhaled correctly RED
Pravilna inhalacija RDEČA
Inhaled human insulin has a duration of glucose lowering activity comparable to subcutaneously administered fast-acting human insulin and longer than fast-acting insulin analogues (see Figure 1).
Trajanje aktivnosti zniževanja glukoze pri humanem insulinu za inhaliranje je primerljivo kot pri subkutano injiciranem hitrodelujočem humanem insulinu in daljše kot pri hitrodelujočih analogih insulina (glejte sliko 1).
Inhaled human insulin is absorbed as rapidly as fast-acting insulin analogues and more rapidly than subcutaneously administered fast-acting human insulin in healthy subjects and in subjects with type 1 or type 2 diabetes (see Figure 4).
Pri zdravih preiskovancih in preiskovancih z diabetesom tipa 1 ali tipa 2 se humani insulin za inhaliranje absorbira enako hitro kot hitrodelujoči insulinski analogi in hitreje kot subkutano aplicirani hitrodelujoči humani insulin (glejte sliko 4).
Inhaled human insulin may be used alone or in combination with oral antidiabetic agents and/or long or intermediate acting subcutaneously administered insulins to optimise glycaemic control.
Humani insulin za inhaliranje lahko uporabljamo samega ali v kombinaciji s peroralnimi antidiabetiki in/ali dolgo- ali srednjedolgo- delujočemi subkutano apliciranimi insulini za optimizacijo glikemične kontrole.
Inhaled human insulin may be used alone or in combination with oral antidiabetic agents and/or long or intermediate acting subcutaneously administered insulins to optimise glycaemic control.
Humani insulin za inhaliranje lahko uporabljamo samega ali v kombinaciji s peroralnimi antidiabetiki in/ali dolgo- ali srednjedolgo- delujočimi subkutano apliciranimi insulini za optimizacijo glikemične kontrole.
Inhaled nitric oxide may have a mild but influence on the platelets (components that help the blood to clot) of you or your child and any signs of bleeding and or haematoma should be observed.
Vdihavanje dušikovega oksida ima lahko pri vas ali vašem otroku blag vpliv na krvne ploščice (komponente, ki pomagajo pri strjevanju krvi), zato morate biti pozorni na kakršnekoli znake krvavitve ali hematoma.
Inhaled nitric oxide therapy may cause an increase in methaemoglobin.
Zdravljenje z vdihavanjem dušikovega oksida lahko povzroči povišanje ravni methemoglobina.
Inhaled nitric oxide therapy should be maintained at 5 ppm until there is improvement in the neonate’s oxygenation such that the FiO2 (fraction of inspired oxygen) < 0.60.
Zdravljenje z vdihavanjem dušikovega oksida obdržite na 5 ppm dokler se oksigenacija novorojenčka ne izboljša tako, da je FiO2 (delež vdihnjenega kisika) <0,60.
inhaled steroids, used to treat hay fever (allergic rhinitis):
inhalirane steroide, ki se uporabljajo za zdravljenje senenega nahoda (alergijski rinitis):
inhaled steroids, used to treat hay fever (allergic rhinitis):
inhalirane steroide, ki se uporabljajo za zdravljenje senenega nahoda (alergijsko vnetje nosne sluznice):
Inhaled/Nasal corticosteroids
Inhalirani/nazalni kortikosteroidi
Inhaled/nasal corticosteroids: Budesonide, fluticasone
Inhalirani/nazalni kortikosteroidi: budezonid, flutikazon
inhaled/nasal fluticasone budesonide
inhalacijski ali nosni flutikazon budezonid
Inhaled/nasal steroid
Inhalacijski/nazalen steroid
Inhaler
inhalator
inhaler (plastic/ stainless steel)
inhalator (plastika/nerjavno jeklo)
inhaler (polycarbonate/stainless steel)
inhalator (polikarbonat/nerjavno jeklo)
Inhaler base
spodnji del inhalatorja
Inhaler Blister card Inhaler base
inhalator pretisni omot spodnji del inhalatorja
Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl metacrylate acrylonitrile butadiene styrene.
Telo in pokrovček inhalatorja sta iz akrilonitril-butadien-stirena, potisni gumbi so narejeni iz metil-metakrilat-akrilonitril- butadien-stirena.
Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl methacrylate acrylonitrile butadiene styrene.
Telo in pokrov inhalatorja sta iz akrilonitril-butadien-stirena, potisni gumbi so, narejeni iz metil-metakrilat-akrilonitril-butadien- stirena.
inhaler containing 120 doses. inhalers each containing 120 doses.
inhalator, ki vsebuje 120 odmerkov. inhalatorja, ki vsebujeta vsak po 120 odmerkov.
inhaler containing 60 doses. inhalers each containing 60 doses.
inhalator, ki vsebuje 60 odmerkov. inhalatorja, ki vsebujeta vsak po 60 odmerkov.
Inhaling Ventavis might trigger breathing difficulties (see section 4), especially in patients with bronchospasm (sudden constriction of the muscles in the walls of the small airways) and wheezing.
Vdihavanje zdravila Ventavis lahko povzroči težave z dihanjem (glejte poglavje 4), predvsem pri bolnikih, ki imajo bronhospazem (nenaden krč mišic v steni majhnih dihalnih poti) in so zasopli.
inherent risk of inducing torsades
povzročitve torsades de pointes ne
Inherently resistant organisms
Po naravi odporni organizmi
Inherently resistant organisms Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei
Naravno odporni organizmi Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei
Inherently resistant organisms:
Naravno odporni mikroorganizmi:
Inherently resistant organisms:
Naravno odporni povzročitelji:
inhibition
Pri sočasnem dajanju
inhibition by
(0,89-0,98)
inhibition by
Ctrough
inhibition by
CYP3A z
inhibition by
CYP3A4 z
inhibition by
ombitasvir/paritap
inhibition by
UPORABL JENO Z
inhibition by
Zavrtje
inhibition by
Zavrtje BCRP s
inhibition by atazanavir.
z atazanavirjem.
inhibition by Kaletra.
Antiepileptiki
inhibition by Kaletra.
Pri uvedbi zdravila Kaletra bo
inhibition by lopinavir/ritonavir,
lopinavirjem/ritonavirjem,
inhibition by lopinavir/ritonavir.
z lopinavirjem/ritonavirjem.
inhibition by lopinavir/ritonavir.
časa uporabe ritonavirja.
inhibition by ritonavir.
ritonavirjem.
inhibition of
zavrtja
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by oral rivastigmine was similar to the inhibition of AChE activity.
Inhibicija aktivnosti butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih s peroralnim rivastigminom, je bila podobna kot inhibicija aktivnosti AChE.
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
Inhibicija aktivnosti butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih z rivastigminom, je bila podobna kot inhibicija AChE.
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
Zaviranje butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih z rivastigminom, je bilo podobno zaviranju AChE.
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Inhibicija karboanhidraze v ciliarnih izrastkih očesa zmanjša izločanje prekatne vodke, verjetno tako, da upočasni nastajanje bikarbonatnih ionov in s tem zmanjša transport natrija in tekočine.
Inhibition of CYP 2C9 with first- dose tipranavir/r, then induction of CYP 2C9 with steady-state tipranavir/r
Zaviranje CYP 2C9 pri prvem odmerku tipranavirja/r, nato indukcija CYP 2C9 pri ravnovesnem stanju tipranavirja/r.
Inhibition of CYP 2D6 by tipranavir/r
Tipranavir/r zavira CYP 2D6.
Inhibition of CYP 3A4 by
CYP 3A4, tipranavir/r pa ga
Inhibition of CYP 3A4 by
Dajanja halofantrina in
Inhibition of CYP 3A4 by
Tipranavir/r zavira CYP 3A4.
Inhibition of CYP 3A4 by tipranavir/r
Tipranavir/r zavira CYP 3A4.
Inhibition of CYP 3A4 by tipranavir/r.
Tipranavir/r zavira CYP3A4.
Inhibition of CYP enzymes including CYP2B6 by dexmedetomidine has been studied in human liver microsome incubations.
Pri inkubaciji mikrosomov v človeških jetrih so preučili inhibicijo encimov CYP, vključno s CYP2B6, ki jo povzroči deksmedetomidin.
Inhibition of CYP1A2
Zaviranje CYP1A2
Inhibition of CYP1A2:
Zaviranje CYP1A2
inhibition of CYP2D6 by
zaviranje CYP2D6 s
inhibition of CYP3A and
zaviranje CYP3A in OATP s
Inhibition of CYP3A and intestinal P-gp may lead to increased plasma levels and pharmacodynamic effects of rivaroxaban which may lead to an increased bleeding risk.
Zaviranje CYP3A in črevesnega P-gp lahko povzroči zvišanje ravni v plazmi in farmakodinamične učinke rivaroksabana, ki lahko povečajo tveganje za krvavitve.
inhibition of CYP3A by
zaviranje CYP3A s
inhibition of CYP3A,
zaviranje CYP3A
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A- dependent metabolism.
Kobicistat z zaviranjem presnove s CYP3A okrepi sistemsko izpostavljenost substratom za CYP3A, kot je atazanavir, ki imajo omejeno biološko uporabnost in kratek razpolovni čas zaradi presnove s CYP3A.
Inhibition of CYP3A.
zaviranje CYP3A
Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life- threatening reactions.
Aprepitant zavira CYP3A4, zaradi česar bi se lahko zvišale plazemske koncentracije teh zdravilnih učinkovin, kar bi lahko povzročilo resne ali življenjsko nevarne reakcije.